<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258245</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000445464</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2869</secondary_id>
    <secondary_id>WSU-HIC-01705M1F</secondary_id>
    <nct_id>NCT00258245</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia</brief_title>
  <official_title>A Phase I Study of Arsenic Trioxide and Ascorbic Acid (ATO/AA) in Combination With Low Dose Velcade-Thalidomide-Dexamethasone (VTD) in Relapsed/Refractory Multiple Myeloma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer&#xD;
      cells more sensitive to the drug. Bortezomib may stop the growth of cancer cells by blocking&#xD;
      some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells&#xD;
      by stopping blood flow to the cancer. Giving arsenic trioxide and ascorbic acid together with&#xD;
      bortezomib, thalidomide, and dexamethasone may stop the growth of and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide&#xD;
      when given together with ascorbic acid, bortezomib, thalidomide, and dexamethasone in&#xD;
      treating patients with relapsed or refractory multiple myeloma or plasma cell leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity of arsenic trioxide when given in combination with&#xD;
           ascorbic acid, bortezomib, thalidomide, and dexamethasone, particularly in terms of&#xD;
           sensory neuropathy, in patients with relapsed or refractory multiple myeloma or plasma&#xD;
           cell leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall response rate, complete response rate, and response duration in&#xD;
           patients treated with the maximum tolerated dose of this regimen.&#xD;
&#xD;
        -  Determine whether the addition of arsenic trioxide and ascorbic acid to the treatment&#xD;
           regimen (beginning in course 2) increases NFKB inhibition in these patients during&#xD;
           courses 2 and 3 compared to course 1.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of arsenic trioxide.&#xD;
&#xD;
        -  Induction therapy: Patients receive bortezomib IV over 3-5 seconds and dexamethasone IV&#xD;
           or orally on days 1, 4, 8, and 11 and oral thalidomide once daily on days 1-21 (course&#xD;
           1). For course 2 and all subsequent courses, patients receive arsenic trioxide IV over&#xD;
           1-2 hours, ascorbic acid IV over 15 minutes, bortezomib IV over 3-5 seconds, and&#xD;
           dexamethasone IV or orally on days 1, 4, 8, and 11 and thalidomide once daily on days&#xD;
           1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
           toxicity. Patients who achieve a plateau in response proceed to maintenance therapy.&#xD;
&#xD;
        -  Maintenance therapy: Patients receive oral dexamethasone every other day and oral&#xD;
           thalidomide once daily in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of arsenic trioxide until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if arsenic trioxide and ascorbic acid at doses up to 0.25 mg/mg/dose can be given in combination with reduced-dose dexamethasone, bortezomib and thalidomide without dose limiting toxicity, especially sensory neuropathies.</measure>
    <time_frame>Days 1, 4, 8 &amp; 11 of each 21 day cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the Overall Response Rate (ORR), Complete Response Rate (CRR), and Response Duration (RD) in patients treated with the Maximally Tolerated Dose (MTD) of this regimen.</measure>
    <time_frame>at cycle 2 and 6 weeks after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if addition of Arsenic Trioxide[AT]/Ascorbic Acid (Vit C)[AA] starting in cycle 2 of treatment increases NF-kappa-B [NFKB] inhibition in cycles 2 and 3 compared to cycle 1.</measure>
    <time_frame>At baseline and 1 hour after the first dose of Bortezomib in cycles 1, 2, and 3</time_frame>
    <description>Peripheral blood samples are to be obtained at baseline, and 1 hour after the first dose of Bortezomib in cycles 1, 2, and 3 for Pharmacodynamic studies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ascorbic acid</intervention_name>
    <description>Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>All Day C CR</other_name>
    <other_name>Ascot</other_name>
    <other_name>C Complex</other_name>
    <other_name>C-500</other_name>
    <other_name>C-500-Gr</other_name>
    <other_name>C-Time</other_name>
    <other_name>Cecon</other_name>
    <other_name>Cemill 1000</other_name>
    <other_name>Cemill 500</other_name>
    <other_name>Centrum Singles-Vitamin C</other_name>
    <other_name>Cevi-Bid</other_name>
    <other_name>N Ice with Vitamin C</other_name>
    <other_name>Special C</other_name>
    <other_name>Sunkist Vitamin C</other_name>
    <other_name>Vicks Vitamin C Drops</other_name>
    <other_name>Vitamin C TR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <description>Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Trisenox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Dexasone</other_name>
    <other_name>Decadron</other_name>
    <other_name>Diodex</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Maxidex</other_name>
    <other_name>Dexamethasone Sodium Phosphate</other_name>
    <other_name>Dexamethasone Acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Thalidomide (Thalomid) - 50 mg/day by mouth (PO)</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin - 325 mg by mouth (PO) every day</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Acuprin 81</other_name>
    <other_name>Anacin Aspirin Regimen</other_name>
    <other_name>Ascriptin</other_name>
    <other_name>Ascriptin Enteric</other_name>
    <other_name>Aspergum</other_name>
    <other_name>Aspidrox</other_name>
    <other_name>Aspir-Low</other_name>
    <other_name>Aspir-Mox</other_name>
    <other_name>Aspir-trin</other_name>
    <other_name>Aspirtab</other_name>
    <other_name>Bayer Aspirin</other_name>
    <other_name>Bufferin</other_name>
    <other_name>Buffex</other_name>
    <other_name>Easprin</other_name>
    <other_name>Ecotrin</other_name>
    <other_name>Ecpirin</other_name>
    <other_name>Empirin</other_name>
    <other_name>Entaprin</other_name>
    <other_name>Entercote</other_name>
    <other_name>Fasprin</other_name>
    <other_name>Genacote</other_name>
    <other_name>Gennin-FC</other_name>
    <other_name>Genprin</other_name>
    <other_name>Halfprin</other_name>
    <other_name>Magnaprin</other_name>
    <other_name>Med Aspirin</other_name>
    <other_name>Migralex</other_name>
    <other_name>Miniprin</other_name>
    <other_name>Minitabs</other_name>
    <other_name>Norwich Aspirin</other_name>
    <other_name>Ridiprin</other_name>
    <other_name>Sloprin</other_name>
    <other_name>St. Joseph Aspirin</other_name>
    <other_name>Uni-Buff</other_name>
    <other_name>Uni-Tren</other_name>
    <other_name>Valomag</other_name>
    <other_name>Zero-Order Release</other_name>
    <other_name>Zorprin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma (MM) or plasma cell leukemia meeting 1 of&#xD;
             the following criteria:&#xD;
&#xD;
               -  Relapsed or refractory disease after treatment with prior effective therapy&#xD;
&#xD;
               -  Exhibited &lt; a partial response to the last therapy&#xD;
&#xD;
          -  Measurable disease, defined by 1 of the following:&#xD;
&#xD;
               -  Serum M protein ≥ 1.0 g/dL&#xD;
&#xD;
               -  Urine M-protein ≥ 500 mg/24 hours&#xD;
&#xD;
               -  Plasmacytoma with bidimensional measurements on CT scan or MRI (each axis ≥ 1 cm)&#xD;
&#xD;
          -  Previously treated with ≥ 1 induction chemotherapy regimen for MM&#xD;
&#xD;
          -  No known CNS involvement by multiple myeloma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod or SWOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 80,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  No history of heparin-induced thrombocytopenia&#xD;
&#xD;
               -  Low blood counts allowed if marrow is heavily infiltrated by multiple myeloma&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  QTc &lt; 480 msec on EKG in the presence of serum potassium ≥ 4.0 mEq/dL and serum&#xD;
             magnesium ≥ 1.8 mg/dL&#xD;
&#xD;
          -  LVEF ≥ 55% by ECHO or MUGA&#xD;
&#xD;
          -  No prior deep vein thrombosis, unless on concurrent anticoagulation&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No history of ventricular arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of allergic reactions or severe adverse reactions attributed to compounds&#xD;
             of similar chemical or biological composition to study drugs&#xD;
&#xD;
          -  No other malignancy in the past 2 years except adequately treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No ongoing or active infection requiring IV antibiotics&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  Controlled HIV disease allowed as long as there are no associated comorbid&#xD;
             complications&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No other condition that would confer a high risk of bleeding complications&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior thalidomide or lenalidomide for MM&#xD;
&#xD;
          -  Prior autologous or allogeneic stem cell transplant for MM allowed&#xD;
&#xD;
          -  Concurrent hematopoietic growth factors (e.g., epoetin alfa, filgrastim [G-CSF]) for&#xD;
             MM allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior arsenic trioxide for MM&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior corticosteroids for MM&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior therapeutic radiotherapy (e.g., to plasmacytomas)&#xD;
&#xD;
               -  Palliative radiotherapy for painful symptomatic lytic skeletal lesions allowed&#xD;
                  within the past 4 weeks&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic agents or other therapy (e.g., bortezomib) for&#xD;
             MM&#xD;
&#xD;
          -  More than 30 days (or 5 half-lives) since prior investigational agents&#xD;
&#xD;
          -  Concurrent bisphosphonates for MM allowed&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A. Zonder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Aspirin, aluminum hydroxide, magnesium hydroxide drug combination</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

